


FIGURE 1A




FIGURE 1B

MPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELK
HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADE
TATIVEFLNRWITFSQSIISTLT

FIGURE 2




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 5A





FIGURE 5B



FIGURES 6A-6B (TOP ROW)
FIGURES 6C-6D (BOTTOM ROW)



1:2 Treg:Tcon
Vehicle
0.3 mg/kg
% Proliferating Cells
(Mean ± SEM)
100
75
50
25
0
0 1 2 3 4 5 6 7 8 9 10
Days post dose

FIGURE 7




FIGURE 8A




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 9C




FIGURE 10A




FIGURE 10B



Protein Level (g/L)
3
2
1
0
SLE + Vehicle
SLE + RUR-IL-2-20kD
Normal Mouse Control
30-Nov-16
7-Dec-16
14-Dec-16
21-Dec-16
28-Dec-16
4-Jan-17
11-Jan-17
18-Jan-17
25-Jan-17
1-Feb-17
8-Feb-17
15-Feb-17
22-Feb-17

FIGURE 11



CD25-bright Tregs, cells/ul
20
15
10
5
0
0
10
20
30
Day
Placebo (Cohorts 1-6)
0.3 ug/kg
1 ug/kg
3 ug/kg
6 ug/kg
9 ug/kg
13.5 µg/kg
Day of administration

FIGURE 11





CD4 Total Tregs, cells/ul
80
60
40
20
0
0
10
20
30
Day
Placebo (Cohorts 1-6)
0.3 ug/kg
1 ug/kg
3 ug/kg
6 ug/kg
9 ug/kg
13.5 µg/kg
Day of administration

FIGURE 13


CD4+ T cells (% of CD3):



CD8+ T cells (% of CD3):



CD8+ T cells (cells/ul):



%Ki67+ CD8+ T cells (% of CD8):




FIGURE 14A-B (TOP ROW)
FIGURE 14C-D (BOTTOM ROW)




FIGURE 15A




FIGURE 15B




FIGURE 16A




FIGURE 16B




FIGURE 17A




FIGURE 17B